The Interaction Between Warfarin and Aspirin on the Risk of Bleeding in Patients with Cardiovascular Disease
Article Sidebar
Main Article Content
Page: 728-739
Abstract
Background: Cardiovascular disease (CVD) remains a leading cause of global morbidity and mortality; therefore, antithrombotic therapy such as warfarin and aspirin plays a crucial role in preventing thromboembolic events. The combination of these two agents provides a synergistic effect in inhibiting thrombus formation but significantly increases the risk of bleeding. Objective: To evaluate the impact of concominant ose of warfarin and aspirin on bleeding risk and its clinical benefits in patients with CVD. Methods: A systematic literature search was conducted using Google Scholar and Pubmed, with eligible studies analyzed. Result: The concomitant use of warfarin and aspirin increases the incidence of major bleeding without providing additional benefits in preventing stroke or myocardial infarction. Moreover, poor anticoagulation control further exacerbates this risk. Conclusion: The combination of warfarin and aspirin should be reserved only for patients with strong clinical indications, while warfarin monotherapy is safer for those with stable conditions. These findings emphasize the importance of individualized therapy evaluation and optimal INR monitoring to balance therapeutic benefits and bleeding risks.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
World Health Organization, “Cardiovascular diseases (CVDs),” World Health Organization.
G. A. Mensah, V. Fuster, C. J. L. Murray, G. A. Roth, and lobal Burden of Cardiovascular Diseases and Risks Collaborators, “Global Burden of Cardiovascular Diseases and Risks, 1990-2022,” J. Am. Coll. Cardiol., vol. 82, no. 25, pp. 2350–2473, 2023, doi: 10.1016/j.jacc.2023.11.007.Global.
D. J. Kumbhani et al., “2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease,” J. Am. Coll. Cardiol., vol. 77, no. 5, pp. 629–658, 2021, doi: 10.1016/j.jacc.2020.09.011.
K. Sridharan and G. Sivaramakrishnan, “Hemorrhage risk associated with triple antithrombotic therapy : a focused real-world pharmacovigilance disproportional analysis study,” BMC Cardiovasc. Disord., vol. 25, no. 180, pp. 1–11, 2025, doi: https://doi.org/10.1186/s12872-025-04510-4.
K. C. Koskinas et al., “Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention,” JACC Cardiovasc. Interv., vol. 9, no. 14, pp. 1473–1483, 2016, doi: 10.1016/j.jcin.2016.04.027.
ESC, “Worse outcomes with aspirin in high-risk chronic coronary syndrome patients who require long-term anticoagulation,” European Society of Cardiology. [Online]. Available: https://www.escardio.org/The-ESC/Press-Office/Press-releases/Worse-outcomes-with-aspirin-in-high-risk-chronic-coronary-syndrome-patients-who-require-long-term-anticoagulation
Z. Nurhafidah, I. L. Hilmi, and H. Sudarjat, “Analysis of the Side Effects of Long-Term Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD),” Heal. Tadulako J. (Jurnal Kesehat. Tadulako), vol. 11, no. 2, pp. 324–335, 2025.
M. Afriliana and E. Yuniarti, “Analisis Bibliometrik Respon Imun Pada Penyakit Leukemia Melalui Aplikasi Vosviewer,” J. Pendidik. Tambusai, vol. 8, no. 02, pp. 17248–177256, 2024.
R. Shah et al., “Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial,” Am. Heart J., vol. 179, pp. 77–86, 2016, doi: 10.1016/j.ahj.2016.05.019.
M. Proietti and G. Y. H. Lip, “Impact of quality of anticoagulation control on outcomes in patients with atrial fi brillation taking aspirin : An analysis from the SPORTIF trials ☆,” Int. J. Cardiol., vol. 252, pp. 96–100, 2018, doi: 10.1016/j.ijcard.2017.10.091.
J. K. Schaefer et al., “Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events,” JAMA Intern. Med., vol. 179, no. 4, pp. 533–541, 2019, doi: 10.1001/jamainternmed.2018.7816.
K. E. Kim, P. Yang, E. Jang, S. Kim, and B. Joung, “Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation : Korean National Health Insurance Service National Cohort,” Yonsei Med. J., vol. 60, no. 1, pp. 65–72, 2019.
C. J.-Y. Lee et al., “Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation,” J. Am. Coll. Cardiol., vol. 69, no. 24, pp. 2901–2909, 2017, doi: 10.1016/j.jacc.2017.04.033.
B. Turan, H. Demir, A. Mutlu, T. Daşlı, A. Erkol, and İ. Erden, “Inappropriate combination of warfarin and aspirin,” Anatol J Cardiol, vol. 16, pp. 189–196, 2016, doi: 10.5152/akd.2015.6050.
Z. M. Dimitrijevic, B. P. Mitic, D. D. Tasic, T. Vrecic, K. Paunovic, and S. Salinger, “Bleeding and Thrombotic Events in Hemodialysis Patients with Atrial Fibrillation on Anticoagulation and Antiplatelet Therapy : A 24-Month Cohort Study,” Medicina (B. Aires)., vol. 60, no. 1760, pp. 1–11, 2024, doi: https://doi.org/10.3390/medicina60111760.
M. L. Boyce, A. Zayac, A. Davis, T. Badrick, Sh. Anoopkumar-Dukie, and N. Bernaitis, “Impact of Aspirin on Warfarin Control as Measured by Time in Therapeutic Range,” Basic Clin. Pharmacol. Toxicol., vol. 123, no. 4, pp. 504–508, 2018, doi: 10.1111/bcpt.13037.
O. A. J. Altisent et al., “Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement,” JACC Cardiovasc. Interv., vol. 9, no. 16, pp. 1706–1717, 2016, doi: 10.1016/j.jcin.2016.06.025.
S. Gulati et al., “Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs : Nationwide pharmacoepidemiological study,” PLoS, vol. 13, no. 8, pp. 1–15, 2018, doi: https://doi.org/10.1371/journal.pone.0202575 August.
G. Hindricks et al., "2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)," European Heart Journal, vol. 42, no. 5, pp. 373–498, Feb. 2021, doi: 10.1093/eurheartj/ehaa612.
A. S. Dewi, Z. Zulkarnain, dan E. N. Sholikhah, "Evaluation of Warfarin Use in Patients with Atrial Fibrillation at a Tertiary Hospital in Indonesia," Indonesian Journal of Pharmacy, vol. 32, no. 4, pp. 508-516, Des. 2021, doi: 10.22146/ijp.1562.
Xu H, Ruff CT, Giugliano RP, Murphy SA, Nordio F, Patel I, et al. Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2016 Feb 23;5(2):e002587. doi:10.1161/JAHA.115.002587.
Watanabe E, Yamamoto M, Kodama I, Inoue H, Atarashi H, Okumura K, et al. Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: insights from the J-RHYTHM Registry. Int J Cardiol. 2016 Mar 19;212:311–7. doi:10.1016/j.ijcard.2016.03.008.